Actinium Pharmaceuticals

Cytarabine is a small-molecule antineoplastic agent indicated for acute myeloid leukemia (AML), sponsored by Actinium Pharmaceuticals under internal code API-01. The program is currently in Phase 2 development with a latest milestone recorded on 20 July 2023. Cytarabine is an established chemotherapy agent with multiple approved formulations globally, including liposomal variants such as DepoCyte. Actinium's development effort represents a continuation or reformulation strategy within an already-approved drug class. The compound is administered via injection and belongs to the L01 therapeutic class (antineoplastic and immunomodulating agents). Regulatory status varies by geography: cytarabine is approved in the United States under multiple abbreviated new drug applications (ANDAs) and one new drug application (NDA), approved in Australia with PBS listings, withdrawn in the European Union (DepoCyte formulation), and currently in clinical trials in China. The program's Phase 2 status indicates ongoing clinical evaluation, with the latest milestone in mid-2023 suggesting active development momentum.

Acute myeloid leukemia remains a serious hematologic malignancy with significant unmet medical need, particularly in elderly and treatment-resistant populations. Cytarabine is a foundational chemotherapy backbone for AML induction and consolidation therapy, making it clinically relevant across multiple patient subgroups. The competitive landscape includes both conventional chemotherapy agents and targeted therapies such as FLT3 inhibitors, IDH inhibitors, and venetoclax combinations. Actinium's Phase 2 program suggests development of a novel formulation or combination strategy to improve efficacy, tolerability, or pharmacokinetic properties over existing cytarabine products. The market relevance is substantial given AML's incidence and the ongoing clinical need for improved therapeutic options. Multiple manufacturers hold approved cytarabine products in the US market (Fresenius Kabi, Teva, Hikma, Jazz Pharmaceuticals, and others), indicating a competitive but established market segment. Actinium's positioning within this space likely targets differentiation through formulation innovation, combination therapy, or improved delivery mechanisms rather than de novo mechanism of action. The Phase 2 milestone in 2023 positions the program for potential Phase 3 initiation or regulatory advancement in the near term.

Drug Class: Antineoplastic and immunomodulating agent (ATC L01)

Modality: Small molecule

Route of Administration: Injection

Mechanism of Action: Not yet disclosed for this program

Target: Not yet disclosed for this program

Related Therapies: Cytarabine is available under multiple brand names and manufacturers globally, including liposomal formulations (DepoCyte/Vyxeos Liposomal). Competitive agents in AML include venetoclax, azacitidine, decitabine, FLT3 inhibitors (Midostaurin), IDH inhibitors (Ivosidenib, Enasidenib), and BCL-2 inhibitors.

First Approval: Cytarabine was first approved in the United States under NDA016793; DepoCyte (liposomal cytarabine) received EMA authorization on 26 June 2017 (EMEA/H/C/000317) but was subsequently withdrawn.

Patent Status: Not yet disclosed for Actinium's API-01 program

• Approved in Australia (Pfizer Australia Pty Ltd) with PBS codes 4357H and 7227J, first listed 1 December 2011
• Approved in the United States under 23 regulatory applications (16 ANDAs, 7 NDAs) by 13 manufacturers
• Withdrawn in the European Union (DepoCyte formulation by Pacira Limited)
• In clinical trials in China (4 active NCT registrations)

United States: Cytarabine is approved under 23 regulatory applications (16 ANDAs and 7 NDAs) by 13 manufacturers including Fresenius Kabi USA, Teva Pharmaceuticals USA, Hikma, Hospira, Jazz Pharmaceuticals Therapeutics, and others. The original NDA (NDA016793) and subsequent approvals (NDA021041, NDA209401) establish cytarabine as a standard-of-care agent.

European Union: DepoCyte (liposomal cytarabine) received EMA authorization on 26 June 2017 under EMEA/H/C/000317 (Marketing Authorization Holder: Pacira Limited) but has been withdrawn from the market.

Australia: Cytarabine (Pfizer Australia Pty Ltd) is approved and listed on the Pharmaceutical Benefits Scheme (PBS) with codes 4357H and 7227J, first listed 1 December 2011.

China: Cytarabine is currently in clinical trials with 4 active NCT registrations (NCT03031262, NCT03356080, NCT04121819, NCT07301138), indicating ongoing clinical development in the Chinese market.

Japan (PMDA): Regulatory status not yet disclosed.

Actinium's API-01 Program: Current regulatory pathway and target approval jurisdiction(s) not yet disclosed.

Strategic Positioning: Actinium's Phase 2 development of cytarabine (API-01) appears to represent a formulation or combination innovation strategy rather than a novel mechanism of action. The program's Phase 2 status as of July 2023 suggests the company is advancing a differentiated cytarabine product, potentially addressing limitations of existing formulations such as neurotoxicity (via liposomal delivery), pharmacokinetics, or combination efficacy.

Competitive Implications: The crowded cytarabine market (13 US manufacturers) and the established position of Vyxeos Liposomal (Jazz Pharmaceuticals) in the liposomal cytarabine space create a challenging competitive environment. Actinium must demonstrate clear clinical or commercial advantages—such as improved tolerability, superior efficacy in specific AML subsets, or favorable pharmacoeconomics—to justify market entry and differentiation.

Regulatory Pathway: The Phase 2 milestone in July 2023 positions the program for potential Phase 3 initiation or regulatory advancement. If successful, the program could target FDA approval via the 505(b)(2) pathway (if a novel formulation) or potentially 505(b)(1) if combination data warrant. The withdrawn DepoCyte precedent in the EU suggests regulatory challenges in that region; Actinium's focus may be on the US and emerging markets (China shows active clinical trial activity).

Future Catalysts: Phase 2 efficacy and safety data readout; Phase 3 initiation announcement; regulatory feedback letters; potential partnership or licensing announcements; comparative efficacy data versus Vyxeos Liposomal or other AML therapies.

• The program's latest milestone (July 2023) suggests active development; next catalyst likely Phase 2 data presentation or Phase 3 initiation within 12–24 months
• Actinium's focus on AML aligns with high unmet medical need, particularly in elderly and relapsed/refractory populations
• Formulation innovation (e.g., liposomal, nanoparticle, or sustained-release) is the most probable differentiation strategy given the established cytarabine market